Meta-analysis of platinum chemotherapy combinations with immunotherapy in metastatic urothelial carcinoma

The therapeutic landscape for metastatic urothelial carcinoma (mUC) has evolved significantly due to the development of innovative combination treatments, including enfortumab vedotin-pembrolizumab (EVP). Despite these advancements, the limited availability of EVP means that platinum-based chemother...

Full description

Saved in:
Bibliographic Details
Published in:The oncologist (Dayton, Ohio) Ohio), 2024-11, Vol.29 (11), p.999-1002
Main Authors: Bolek, Hatice, Yazgan, Satı Coskun, Yekedüz, Emre, Ürün, Yüksel
Format: Article
Language:English
Subjects:
Antimitotic agents
Antineoplastic agents
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bladder cancer
Brief Communication
Carboplatin - administration & dosage
Carboplatin - therapeutic use
Carcinoma, Transitional Cell - drug therapy
Carcinoma, Transitional Cell - mortality
Carcinoma, Transitional Cell - pathology
Chemotherapy, Combination
Cisplatin - administration & dosage
Cisplatin - therapeutic use
Deoxycytidine - administration & dosage
Deoxycytidine - analogs & derivatives
Deoxycytidine - therapeutic use
Dosage and administration
Drug therapy
Gemcitabine
Humans
Immunotherapy
Immunotherapy - methods
Metastasis
Methods
Neoplasm Metastasis
Patient outcomes
Urinary Bladder Neoplasms - drug therapy
Urinary Bladder Neoplasms - mortality
Urinary Bladder Neoplasms - pathology
Urologic Neoplasms - drug therapy
Urologic Neoplasms - pathology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The therapeutic landscape for metastatic urothelial carcinoma (mUC) has evolved significantly due to the development of innovative combination treatments, including enfortumab vedotin-pembrolizumab (EVP). Despite these advancements, the limited availability of EVP means that platinum-based chemotherapy regimens continue to serve as the primary treatment modality for many patients with mUC. We evaluated the effect of the type of platinum chemotherapy used in combination with immunotherapy (IO) on treatment outcomes in mUC. The meta-analysis showed that cisplatin-gemcitabine plus IO combination and carboplatin-gemcitabine plus IO combination improve progression-free survival compared to platinum-gemcitabine therapy (hazard ratio [HR] = 0.71, 95% CI: 0.62-0.82; P 
ISSN:1083-7159
1549-490X
1549-490X
DOI:10.1093/oncolo/oyae243